You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Asthma and COPD Guidelines and Guidance

Health Technology Appraisal (HTA) guidance for Relvar Ellipta

Asthma

Relvar Ellipta 92/22 mcg
Relvar Ellipta 184/22 mcg

See the Scottish Medicines Consortium website (SMC) for guidance on Relvar in asthma  [1]

SMC Advice

following a full submission:

fluticasone furoate / vilanterol (Relvar Ellipta®) is accepted for use within NHS Scotland.

Indication under review: the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.

There was no statistically significant difference between fluticasone furoate/vilanterol 92/22 micrograms daily and another inhaled corticosteroid/long acting beta2-agonist combination (ICS/LABA) inhaler for 0 to 24 hour serial weighted mean forced expiratory volume in one second, at 24 weeks.

Some alternative ICS/LABA combination inhalers are available at a lower daily cost.

See the All Wales Medicines Strategy Group website (AWMSG) for guidance on Relvar in asthma[2]

AWMSG Advice

Fluticasone furoate/vilanterol (Relvar® Ellipta®) is recommended as an option for use within NHS Wales for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.

COPD

Relvar Ellipta 92/22 mcg

See the Scottish Medicines Consortium website (SMC) for guidance on Relvar in COPD[3]

SMC Advice

following a full submission:

fluticasone furoate/vilanterol (Relvar Ellipta®) is accepted for restricted use within NHS Scotland.

Indication under review: symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.

SMC restriction: in patients with severe COPD (FEV1 <50% predicted normal).

In a comparative, 12-week study there was no statistically significant difference between fluticasone furoate/vilanterol 92/22 micrograms and another inhaled corticosteroid/long acting beta agonist combination inhaler for change from baseline trough in 24-hour weighted-mean FEV1.

See the All Wales Medicines Strategy Group website (AWMSG) for guidance on Relvar in COPD [4]

AWMSG Advice

Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) is recommended as an option for use within NHS Wales for the symptomatic treatment of adults with chronic obstructive pulmonary disease with a FEV1< 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.

BTS/SIGN asthma guideline [5]
You can access the guideline from: www.brit-thoracic.org.uk

NICE 2010 COPD Guideline [6]
You can access the guideline from: www.nice.org.uk/guidance/CG101

Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD Guideline [7]
You can access the guideline from: www.goldcopd.org

Reference:

  1. Scottish Medicines Consortium, Fluticasone furoate / vilanterol (Relvar Ellipta®) asthma guidance, Glasgow, 2014.
  2. All Wales Medicines Strategy Group, Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®). Reference No. 1216. 2014.
  3. Scottish Medicines Consortium, Fluticasone furoate / vilanterol (Relvar Ellipta®) COPD guidance, Glasgow, 2014.
  4. All Wales Medicines Strategy Group, Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®). Reference No. 1534. 2014.
  5. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma 2016
  6. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). London: National Clinical Guideline Centre; 2010.
  7. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available and adapted from http://www.goldcopd.org/. Accessed December 2016.
Innoviva logo

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Relvar, Incruse and Ellipta are registered trademarks of the GlaxoSmithKline group of companies